Application and Progress of Targeted Drug Therapy for Colorectal Cancer
- 1 January 2021
- journal article
- Published by Hans Publishers in World Journal of Cancer Research
- Vol. 11 (01), 24-31
- https://doi.org/10.12677/wjcr.2021.111004
Abstract
在我国,结直肠癌发病率呈逐年增加趋势,靶向药物联合化疗已成为晚期结直肠癌治疗的趋势所在,近几年随着靶向药物治疗的应用,很大程度上延长了晚期结直肠癌患者的生存期。同时,由于对结直肠癌病因学、分子生物学、细胞学的不断升入研究及相关试验开展,新的靶向药物不断涌现。本文综述了结直肠癌靶向治疗的临床应用与研究进展。 In China, the incidence rate of colorectal cancer is increasing year by year. Targeted drug combination chemotherapy has become the trend of treatment for advanced colorectal cancer. In recent years, with the application of targeted drug therapy, the survival time of patients with advanced colorectal cancer has been greatly extended. At the same time, with the development of the research on the etiology, molecular biology and cytology of colorectal cancer, new targeted drugs are emerging. This paper reviews the clinical application and research progress of targeted therapy for colorectal cancer.Keywords
This publication has 38 references indexed in Scilit:
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal CancerThe New England Journal of Medicine, 2013
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based RegimenJournal of Clinical Oncology, 2012
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2Journal of Clinical Oncology, 2010
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerThe New England Journal of Medicine, 2008
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- 3001 ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC)European Journal of Cancer Supplements, 2007
- FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal CancerThe Oncologist, 2007
- Cellular abnormalities of blood vessels as targets in cancerCurrent Opinion in Genetics & Development, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerThe New England Journal of Medicine, 2004